RxDoctor Payments Data

Susan Leonard, MD

Rheumatology · Edina, MNNPI 1831180736

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 29 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Amgen at 34.7% of the total. Reporting peaked in 2019 at $176 and has fallen 53.9% since, to $81 in 2025.

$485in general payments, 2019–2025

Across 29 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$168
  • Johnson & Johnson$74
  • AbbVie$52
  • Fresenius Kabi USA, LLC$43
  • UCB, Inc.$39
  • Sanofi$32
  • plus $77 from 5 others

What the payments were for

  • Food & beverage$485100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$485 in reported general payments places this provider in the 65th percentile of 121 rheumatology providers in Minnesota.

See all rheumatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$1,495,779
Medicare patients
340
Services billed
106,963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept63$524,671
Enbrel SureclickEtanercept30$224,367
Humira(Cf) PenAdalimumab25$213,536
Humira PenAdalimumab12$166,423
OtezlaApremilast27$161,589
MethotrexateMethotrexate Sodium622$20,088
Hydroxychloroquine Sulfate277$13,373
Leflunomide131$9,145
Prednisone588$6,059
Sulfasalazine89$4,159
Mycophenolate Mofetil25$2,436
Celecoxib37$2,122
Methylprednisolone68$1,898
Allopurinol105$1,773
Azathioprine22$949

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$168$686,26190 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 121 rheumatology providers in Minnesota.

Other rheumatology in Edina

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →